Canada markets closed

Clearside Biomedical, Inc. (CLSD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.5300-0.1400 (-8.38%)
At close: 04:00PM EDT
1.5901 +0.06 (+3.93%)
After hours: 07:22PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close1.6700
Open1.6600
Bid1.5100 x 300
Ask1.5700 x 300
Day's Range1.5000 - 1.7200
52 Week Range0.6500 - 2.1200
Volume441,649
Avg. Volume353,122
Market Cap114.323M
Beta (5Y Monthly)2.29
PE Ratio (TTM)N/A
EPS (TTM)-0.5300
Earnings DateMay 09, 2024 - May 13, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.50
  • GlobeNewswire

    Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

    Industry Veteran with Extensive Experience in Retinal Disease Research and Strong Track Record in Advancing Programs Through Clinical Development Victor Chong, M.D., MBA Victor Chong, M.D., MBA was appointed as Chief Medical Officer for Clearside Biomedical. ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced to

  • Simply Wall St.

    Clearside Biomedical Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line

    Clearside Biomedical ( NASDAQ:CLSD ) Full Year 2023 Results Key Financial Results Revenue: US$8.23m (up by US$6.90m...

  • Insider Monkey

    Clearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2023 Earnings Call Transcript

    Clearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2023 Earnings Call Transcript March 13, 2024 Clearside Biomedical, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings, and welcome to the Clearside Biomedical Q4 2023 Financial Results and Corporate Update Call. At this […]